Bowel Ultrasound: a Non-invasive, Easy to Use Method to Predict the Need to Intensify Therapy in Inflammatory Bowel Disease Patients.

BACKGROUND AND AIMS Bowel ultrasound (BU) is a non-invasive, inexpensive, widely available tool, valuable for inflammatory bowel disease (IBD) assessment. The aim of the present study was to investigate the clinical utility of BU to predict the need to intensify therapy in IBD patients. METHODS One hundred seventeen IBD patients (89 Crohn's disease, and 28 ulcerative colitis) diagnosis established at least 6 months before enrolment, undergoing maintenance therapy were prospectively included in the study. Bowel ultrasound investigated the following parameters: the bowel wall thickness (BWT), loss of wall stratification, the presence of the bowel wall Doppler signal, the visible lymph nodes, the mucosal hyperechoic spots, and the irregular external bowel wall. The patients were followed-up for 6 months, registering the need to escalate the treatment regimen. Subgroup analyses were conducted for patients requiring immediate treatment intensification (37 subjects), due to active disease at baseline and patients with subsequent treatment intensification, in the 6 months follow-up period (21 cases) in comparison to patients that required no therapeutic optimization (59). RESULTS During the follow-up, 49.6% of patients needed treatment escalation. All the investigated BU variables were significantly associated with the main outcome. In the multivariate analysis, the mean BWT (p<0.0001), and the presence of the bowel wall Doppler signal (p=0.007) were independent predictors of the main outcome. For the subgroup analyses: mean BWT (p=0.0001) and the presence of the bowel wall Doppler signal (p=0.01) were independent predictors for immediate treatment intensification (active disease at baseline) and mean BWT (p=0.0003) and the lack of bowel wall stratification (p=0.05) were independent predictors for the need of subsequent therapeutic optimization. Logistic regression prediction models and prediction scores (BU score) had the best AUROC values (>0.91) when compared to traditional biomarkers of active inflammation, such as C reactive protein or fecal calprotectin. CONCLUSION Bowel ultrasound could be used as a non-invasive, easy to use diagnostic tool to predict the need to intensify therapy in patients with IBD.

[1]  G. D'Haens,et al.  Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index , 2021, Journal of Crohn's & colitis.

[2]  M. Allocca,et al.  Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn’s Disease , 2020, Journal of Crohn's & colitis.

[3]  O. Gilja,et al.  Development and Validation of a Simple Ultrasound Activity Score for Crohn’s Disease , 2020, Journal of Crohn's & colitis.

[4]  J. Rioux,et al.  Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures , 2019, BMC Gastroenterology.

[5]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[6]  S. Bonovas,et al.  Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study , 2018, Journal of Crohn's & colitis.

[7]  P. Gibson,et al.  Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application , 2018, Gut.

[8]  S. Vasikaran,et al.  Faecal calprotectin , 2018, Radiopaedia.org.

[9]  Stephanie R. Wilson,et al.  Role of contrast-enhanced ultrasound in evaluation of the bowel , 2017, Abdominal Radiology.

[10]  D. Tanyingoh,et al.  A Simple Ultrasound Score for the Accurate Detection of Inflammatory Activity in Crohn's Disease , 2017, Inflammatory bowel diseases.

[11]  P. V. van Rheenen,et al.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide , 2017, Inflammatory bowel diseases.

[12]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[13]  T. Kucharzik,et al.  The use of ultrasound in inflammatory bowel disease , 2016, Annals of gastroenterology.

[14]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[15]  S. Hanauer.  The Use of Fecal Calprotectin in Inflammatory Bowel Disease , 2017 .

[16]  C. Dietrich,et al.  EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound - Part 1: Examination Techniques and Normal Findings (Short version) , 2016, Ultraschall in der Medizin - European Journal of Ultrasound.

[17]  L. Sconfienza,et al.  Contrast-enhanced Ultrasound for Detection of Crohn's Disease Activity: Systematic Review and Meta-analysis. , 2016, Journal of Crohn's & colitis.

[18]  D. Tanyingoh,et al.  Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. , 2015, Journal of Crohn's & colitis.

[19]  Jacob E. Kurlander,et al.  A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS , 2015, The American Journal of Gastroenterology.

[20]  L. Biancone,et al.  A sonographic lesion index for Crohn's disease helps monitor changes in transmural bowel damage during therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  C. Beglinger,et al.  The use of fecal calprotectin as a biomarker in gastrointestinal disease , 2014, Expert review of gastroenterology & hepatology.

[22]  G. Fiorino,et al.  Cross-Sectional Imaging Modalities in Crohn's Disease , 2013, Digestive Diseases.

[23]  N. Caporaso,et al.  Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics , 2013, Inflammatory bowel diseases.

[24]  L. Biancone,et al.  Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. , 2012, Journal of Crohn's & colitis.

[25]  S. Gallus,et al.  Bowel Ultrasound and Mucosal Healing in Ulcerative Colitis , 2009, Digestive Diseases.

[26]  M. Daperno,et al.  Abdominal bowel ultrasound can predict the risk of surgery in Crohn's disease: Proposal of an ultrasonographic score , 2009, Scandinavian journal of gastroenterology.

[27]  Roelof J Bennink,et al.  Magnetic resonance imaging in Crohn's disease , 2008 .

[28]  G. Porro,et al.  Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis. , 1999, Scandinavian journal of gastroenterology.